Lion's Mane for Nerve Growth Factor

Lion's Mane (Hericium erinaceus) is the only mushroom in the world demonstrated to stimulate Nerve Growth Factor (NGF), the foundational neurotrophin that Rita Levi-Montalcini and Stanley Cohen won the 1986 Nobel Prize in Physiology or Medicine for discovering. The Japanese chemist Hirokazu Kawagishi isolated the first hericenone NGF-stimulating compounds (hericenones B-H) from the fruit body in 1991 and the erinacines (A-K) from mycelium in 1994. Erinacine A is the only mushroom-derived molecule small enough (498 Da) and lipophilic enough to cross the blood-brain barrier intact and stimulate central NGF synthesis directly. Hericenones, by contrast, are concentrated in the white above-ground fruit body but do not cross the BBB efficiently — they appear to act peripherally on the enteric nervous system and indirectly support central NGF tone. Because NGF is specifically required for the survival of cholinergic basal forebrain neurons — the exact population that dies progressively in Alzheimer's disease — this mushroom has accumulated more neurodegenerative-disease research attention than any other dietary fungus.

Table of Contents

  1. What Is Nerve Growth Factor?
  2. The Kawagishi Discovery (1991 & 1994)
  3. Hericenones vs Erinacines
  4. Why Erinacine A Crosses the Blood-Brain Barrier
  5. Fruit Body vs Mycelium — The Product Selection Decision
  6. NGF and Cholinergic Basal Forebrain Neurons
  7. The Alzheimer's Connection
  8. Peripheral Nerve Regeneration
  9. BDNF and Hippocampal Neurogenesis
  10. Practical Dose and Form for NGF Effects
  11. Cautions and Drug Interactions
  12. Key Research Papers
  13. Connections

What Is Nerve Growth Factor?

Nerve Growth Factor (NGF) is a 26 kilodalton protein and the founding member of the neurotrophin family — a small set of secreted proteins (NGF, BDNF, NT-3, NT-4) that specific neuron populations require for survival, axon growth, dendritic arborization, and synaptic plasticity. NGF was discovered by Rita Levi-Montalcini and Stanley Cohen in the 1950s in the now-famous experiment in which mouse sarcoma cells transplanted into chick embryos caused massive nerve fiber outgrowth toward the tumor. The pair was awarded the 1986 Nobel Prize in Physiology or Medicine for the discovery, which fundamentally changed the understanding of how the nervous system is built and maintained.

NGF binds two receptors on neuronal surfaces: TrkA, the high-affinity tyrosine kinase receptor that drives survival, axon growth, and trophic responses; and p75NTR, the low-affinity receptor that can in some contexts drive apoptosis (programmed cell death) when NGF is scarce. The TrkA-expressing neurons that depend most acutely on NGF are cholinergic basal forebrain neurons in the medial septum, the diagonal band of Broca, and the nucleus basalis of Meynert — the same neurons that progressively die in Alzheimer's disease, producing the cholinergic deficit that the cholinesterase inhibitor class of Alzheimer's drugs (donepezil, rivastigmine, galantamine) attempts to compensate for symptomatically.

NGF cannot be administered as a drug. It is a large, polar protein that does not cross the blood-brain barrier and that is degraded rapidly in serum. Intranasal and intracerebroventricular NGF delivery have been tested in small clinical trials with modest results and significant side effects. The Lion's Mane discovery — that small-molecule mushroom-derived compounds can stimulate endogenous NGF synthesis in the brain — represents a fundamentally different and potentially more practical therapeutic approach.

Back to Table of Contents

The Kawagishi Discovery (1991 & 1994)

The Lion's Mane NGF story begins with one Japanese chemist: Hirokazu Kawagishi, then at Shizuoka University. Kawagishi was systematically screening edible mushrooms for compounds that would stimulate NGF synthesis in cultured mouse astroglial cells (1321N1 human astrocytoma cells in later work) when he found that ethanolic extracts of Lion's Mane fruit body produced a striking NGF response.

The 1991 paper (Kawagishi et al., Tetrahedron Letters) reported isolation of three novel aromatic compounds — hericenones B, C, and D — from the fruit body of Hericium erinaceum (later reclassified as Hericium erinaceus). Subsequent papers extended the family to hericenones E, F, G, and H. All of the hericenones share a common cerebroside-like aromatic backbone with an acyl chain attached to a phenol. Their NGF-stimulating activity in cultured cells is significant but the compounds themselves are too polar to cross the blood-brain barrier intact.

The breakthrough came three years later. In 1994, the same Kawagishi group reported isolation of a structurally distinct compound family — the erinacines — from the underground mycelial network of Lion's Mane. The first three members (erinacines A, B, and C) were cyathane-type diterpenoids with much smaller molecular weights and far greater lipophilicity than the hericenones. Erinacines D, E, F, G, H, I, J, and K followed in later papers. Critically, oral administration of erinacine A in rats produced measurable elevation of NGF in the locus coeruleus and hippocampus — demonstrating that this single compound was reaching the brain intact and stimulating central NGF synthesis. No other mushroom-derived molecule has matched that pharmacokinetic profile.

Back to Table of Contents

Hericenones vs Erinacines

The two compound families have fundamentally different chemistry and consequently different biological action:

The practical consequence is that the two compound families are complementary, not interchangeable. The fruit body alone misses the central erinacine A effect. The mycelium alone misses the peripheral hericenone effect (and may have lower erinacine content than expected if the artificial grain substrate doesn't trigger erinacine production). A dual extract that combines fruit body and mycelium is the format most likely to deliver both compound families at validated doses.

This is not a marketing distinction — it is the central scientific finding of the Kawagishi work. Any Lion's Mane product label that does not specify whether the source is fruit body, mycelium, or both is providing incomplete information.

Back to Table of Contents

Why Erinacine A Crosses the Blood-Brain Barrier

The blood-brain barrier (BBB) is a selective permeability layer formed by tight junctions between brain capillary endothelial cells, supported by pericytes and astrocyte end-feet. It excludes most polar small molecules, all proteins, and most therapeutic drugs. Three properties predict whether a small molecule will cross the BBB by passive diffusion:

  1. Molecular weight under ~500 Da — the practical upper bound for efficient passive transcellular diffusion
  2. Lipophilicity (log P between 1 and 3) — molecules need enough lipid solubility to partition into the membrane bilayer but not so much that they get trapped there
  3. Low hydrogen-bond donor count and small polar surface area — reduces the energetic cost of stripping water from the molecule as it enters the membrane

Erinacine A satisfies all three criteria. Its molecular weight is 498 Da (just under the threshold), it is a cyathane diterpene with a hydrophobic terpenoid skeleton, and its polar surface area is modest. Hericenones, by contrast, exceed the polar surface area threshold and carry the large polar cerebroside head group that anchors them to the lipid bilayer without easy passage to the brain side.

This is rare. Most small-molecule natural products either lack the lipophilicity to cross (most polyphenols, most water-soluble vitamins) or, if they do cross, lack a defined central pharmacology. Erinacine A combines BBB penetration with a specific, validated central effect (NGF synthesis induction in basal forebrain cholinergic neurons), which is what makes it pharmacologically interesting. The closest analogues are some of the alkaloids found in caffeine, nicotine, and the cannabinoid family — small lipophilic plant-derived molecules with specific central receptor targets.

Back to Table of Contents

Fruit Body vs Mycelium — The Product Selection Decision

The Lion's Mane supplement market is dominated by three product formats, with very different cost and quality profiles:

For a person whose primary goal is cognitive support, BBB-crossing erinacine A coverage matters and a dual extract or pure mycelium-without-grain extract is preferable. For a person whose primary goal is gut health, polysaccharide content matters more and a hot-water fruit-body extract is sufficient. For a person who simply wants to add Lion's Mane to a generally health-promoting diet without targeting a specific neurological outcome, fresh culinary Lion's Mane fruit body (available at well-stocked grocery stores in the U.S. since the late 2010s) is a reasonable choice and avoids the supplement-grade quality concerns entirely.

Back to Table of Contents

NGF and Cholinergic Basal Forebrain Neurons

NGF is most critical for one specific neuron population: the cholinergic basal forebrain neurons. These large projection neurons sit in three anatomically connected nuclei — the medial septum, the diagonal band of Broca, and the nucleus basalis of Meynert — and send acetylcholine-releasing axons throughout the hippocampus and cerebral cortex. They are the principal source of acetylcholine to the forebrain, and acetylcholine is the principal neurotransmitter underlying attention, working memory, and short-term encoding of new information.

These neurons express high levels of the TrkA NGF receptor and depend on NGF, retrogradely transported back from their cortical and hippocampal targets, for survival across adult life. When NGF supply is reduced experimentally (lesion of the projection target, anti-NGF antibody administration, or genetic knockout of NGF or TrkA), cholinergic basal forebrain neurons atrophy and eventually die, producing characteristic cognitive deficits.

In Alzheimer's disease, this exact neuron population progressively dies, producing the cholinergic deficit that the cholinesterase inhibitor drugs (donepezil/Aricept, rivastigmine/Exelon, galantamine/Razadyne) attempt to compensate for by reducing acetylcholine breakdown. The cholinesterase inhibitors do not slow the underlying neuron loss; they only extract more transmitter from each surviving neuron. A treatment that could preserve the basal forebrain cholinergic neurons themselves — by maintaining their NGF supply — would in principle modify the disease course rather than only its symptoms. This is the conceptual basis for the substantial preclinical attention Lion's Mane has received in Alzheimer's research.

Back to Table of Contents

The most studied animal model of Lion's Mane in neurodegeneration is the 5xFAD transgenic mouse, which carries five familial Alzheimer's disease mutations and develops dense amyloid-beta plaques and behavioral deficits at predictable ages. The Tsai-Teng et al. 2016 paper (Journal of Biomedical Science) treated 5xFAD mice with erinacine A-enriched Lion's Mane mycelium and found:

Multiple subsequent animal studies have replicated subsets of these findings with various Lion's Mane preparations. The human translation remains preliminary but encouraging: the Mori 2009 trial in Japanese adults 50-79 with mild cognitive impairment showed progressive cognitive improvement on the Hasegawa Dementia Scale-Revised (HDS-R) at weeks 8, 12, and 16 of supplementation, with regression at week 20 (four weeks after stopping). This is exactly the dose-response pattern expected of a neurotrophic effect — benefit accumulates over weeks of administration and dissipates over weeks after discontinuation, as would be expected if the mechanism is sustained NGF support of vulnerable neurons rather than acute pharmacological effect.

Larger, longer randomized trials in early Alzheimer's disease and in mild cognitive impairment (the prodromal stage that converts to Alzheimer's at approximately 10-15% per year) are needed. The available evidence is sufficient to justify Lion's Mane as a reasonable adjunct in mild cognitive impairment care — particularly given the favorable safety profile — but not yet sufficient to make claims of disease modification in established Alzheimer's. The Alzheimer's Disease page covers the broader nutritional and lifestyle approach to dementia prevention.

Back to Table of Contents

Peripheral Nerve Regeneration

NGF also drives axon growth and regeneration in the peripheral nervous system. The Wong et al. crushed-sciatic-nerve studies (University of Malaya, 2010s) administered Lion's Mane extract to rats following surgical crush injury of the sciatic nerve and showed accelerated functional recovery, faster restoration of compound muscle action potential amplitude, and improved axon regrowth on histological examination compared to untreated controls. Earlier work from the same group with a peroneal nerve transection model showed similar acceleration of recovery.

The clinical translation to humans with peripheral neuropathy (diabetic, chemotherapy-induced, idiopathic small-fiber) is plausible but not yet well-tested. Case reports and small open-label series suggest symptomatic benefit, but no randomized placebo-controlled trial in human peripheral neuropathy has been published at a scale that would support evidence-based recommendation. Patients with established peripheral neuropathy who wish to try Lion's Mane as adjunct should do so alongside — not in place of — standard care, with attention to glycemic control, alcohol cessation, and B-vitamin status. See the Peripheral Neuropathy page for the broader approach.

The proposed mechanism is the same NGF/BDNF effect demonstrated in cell culture and central animal models. Hericenones in the fruit body likely contribute on the peripheral side, since their inability to cross the BBB is irrelevant for peripheral nerve targets and they reach peripheral tissues unimpeded after oral absorption.

Back to Table of Contents

BDNF and Hippocampal Neurogenesis

Beyond NGF, Lion's Mane preparations have been shown to upregulate Brain-Derived Neurotrophic Factor (BDNF) in the hippocampus. BDNF is the neurotrophin most closely associated with adult hippocampal neurogenesis — the ongoing production of new neurons in the subgranular zone of the dentate gyrus throughout adult life — and with synaptic plasticity in the hippocampus generally.

BDNF is a separate research story from NGF but overlaps with it functionally: both are TrkA/TrkB-family neurotrophins that support neuronal survival, growth, and plasticity. The hippocampal BDNF effect is mechanistically relevant to several of Lion's Mane's documented benefits:

This is the molecular bridge that links Lion's Mane's cognitive effects to its mood effects: both depend on the same neurotrophin-driven hippocampal plasticity, just expressed in different cognitive and affective domains. The Mood and Depression page develops the depression-specific evidence in more detail.

Back to Table of Contents

Practical Dose and Form for NGF Effects

The doses used in the major human trials provide a practical starting range:

The practical synthesis: 1-3 g per day of a quality Lion's Mane preparation, ideally a dual extract that combines fruit body and mycelium-without-grain, taken with meals for at least 8-12 weeks before assessing effect. The slow onset matters — readers expecting a stimulant-like acute response will not find one. The cognitive benefit observed in Mori 2009 was not measurable at the 4-week assessment; it appeared at week 8 and grew through week 16. A 2-week trial of any Lion's Mane preparation is not informative.

For people who can find it fresh, culinary Lion's Mane fruit body (sauteed in butter or olive oil) is a pleasant way to get a meaningful dose — the texture resembles crab meat or scallop and the flavor is mild and savory. A 100 g fresh portion provides on the order of 20-25 g dry-weight equivalent fruit body. Fresh fruit body alone will not deliver the BBB-crossing erinacine A from mycelium, but it does deliver the full hericenone content along with the polysaccharides, beta-glucans, and other nutrients of the whole food.

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Kawagishi H et al. (1991). Hericenones C, D and E, stimulators of nerve growth factor (NGF)-synthesis, from the mushroom Hericium erinaceum. Tetrahedron Letters. — PubMed
  2. Kawagishi H et al. (1994). Erinacines A, B and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of Hericium erinaceum. Tetrahedron Letters. — PubMed
  3. Mori K et al. (2008). Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biological & Pharmaceutical Bulletin. — PubMed
  4. Mori K et al. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment. Phytotherapy Research. — PubMed
  5. Tsai-Teng T et al. (2016). Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice. Journal of Biomedical Science. — PubMed
  6. Wong KH et al. (2011). Peripheral nerve regeneration following crush injury to rat peroneal nerve by aqueous extract of medicinal mushroom Hericium erinaceus. Evidence-Based Complementary and Alternative Medicine. — PubMed
  7. Lai PL et al. (2013). Neurotrophic properties of the Lion's mane medicinal mushroom, Hericium erinaceus: a review. International Journal of Medicinal Mushrooms. — PubMed
  8. Friedman M (2015). Chemistry, nutrition, and health-promoting properties of Hericium erinaceus mushroom fruiting bodies and mycelia. Journal of Agricultural and Food Chemistry. — PubMed
  9. Phan CW et al. (2015). Therapeutic potential of culinary-medicinal mushrooms for the management of neurodegenerative diseases. Critical Reviews in Biotechnology. — PubMed
  10. Mori K et al. (2011). Effects of Hericium erinaceus on amyloid-beta(25-35) peptide-induced learning and memory deficits in mice. Biomedical Research. — PubMed
  11. Levi-Montalcini R (1987). The nerve growth factor 35 years later. Science. — PubMed
  12. Cohen S, Levi-Montalcini R, Hamburger V (1954). A nerve growth-stimulating factor isolated from sarcomas. PNAS. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents